Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
Total Valuation
Clearside Biomedical has a market cap or net worth of $57.89M. The enterprise value is $104.51M.
Market Cap$57.89M
Enterprise Value$104.51M
Share Statistics
Clearside Biomedical has 77.28M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77.28M
Owened by Insiders1.83%
Owened by Instutions4.12%
Financial Efficiency
Clearside Biomedical’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -139.48%.
Return on Equity (ROE)88.41%
Return on Assets (ROA)-136.72%
Return on Invested Capital (ROIC)-139.48%
Return on Capital Employed (ROCE)-142.05%
Revenue Per Employee$240,718.75
Profits Per Employee-$996,156.25
Employee Count32
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clearside Biomedical is -2.04. Clearside Biomedical’s PEG ratio is 0.18.
PE Ratio-2.04
PS Ratio0.00
PB Ratio-1.80
Price to Fair Value-1.80
Price to FCF-2.84
Price to Operating Cash Flow-2.84
PEG Ratio0.18
Income Statement
In the last 12 months, Clearside Biomedical had revenue of $7.70M and earned -$31.88M in profits. Earnings per share was -$0.45.
Revenue$7.70M
Gross Profit$7.66M
Operating Income-$24.65M
Pretax Income-$31.88M
Net Income-$31.88M
EBITDA-22.23M
Earnings Per Share (EPS)-0.45
Cash Flow
In the last 12 months, operating cash flow was -$18.95M and capital expenditures -$653.00K, giving a free cash flow of -$19.60M billion.
Operating Cash Flow-$18.95M
Free Cash Flow-$19.60M
Free Cash Flow per Share-$0.25
Dividends & Yields
Clearside Biomedical pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-35.23%
Earnings Yield-49.00%
Stock Price Statistics
Beta1.45
52-Week Price Change-39.20%
50-Day Moving Average0.94
200-Day Moving Average1.06
Relative Strength Index (RSI)44.41
Average Volume (3m)211.18K
Important Dates
Clearside Biomedical upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Clearside Biomedical as a current ratio of 4.44, with Debt / Equity ratio of -0.02
Current Ratio4.44
Quick Ratio4.44
Debt to Market Cap0.01
Net Debt to EBITDA0.67
Interest Coverage Ratio2.95
Taxes
In the past 12 months, Clearside Biomedical has paid -$6.58M in taxes.
Income Tax-$6.58M
Effective Tax Rate0.00%
Enterprise Valuation
Clearside Biomedical EV to EBITDA ratio is -1.76, with an EV/FCF ratio of -2.06.
EV to Sales0.00
EV to EBITDA-1.76
EV to Free Cash Flow-2.06
EV to Operating Cash Flow-2.06
Balance Sheet
Clearside Biomedical has $23.59M in cash and marketable securities with $785.00K in debt, giving a net cash position of -$22.81M billion.
Cash & Marketable Securities$23.59M
Total Debt$785.00K
Net Cash-$22.81M
Net Cash Per Share-$0.30
Tangible Book Value Per Share-$0.53
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Clearside Biomedical is $5.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.80
Price Target Upside663.16%
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-79.77%
EPS Growth Forecast10.85%